European Psychiatry - Volume 33 - March 2016

66 / 812

S62 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S56–S71
2 Institute of Psychological Medicine IPM, Department of Psychiatry,
Psychotherapy, Ludwig-Maximilians-University, Haag o.B., Germany
∗ Corresponding author.
Introduction In most European countries postgraduate training
for specialization in psychiatry and psychotherapy is acquired over
the course of 4–6-year programs. In the European Union, qualifi-
cation in one country is recognized within other countries of the
Union.
Objectives and aims To analyze the present situation of
psychopharmacology-pharmacopsychiatry postgraduate teaching
in Europe and to present the needs and preliminary instruments
for improving the situation by harmonization of the programs.
Methods Analysis of the data available from national psychi-
atric societies and from the literature; development of a consensus
among experts in this field.
Results Despite efforts to standardize post-graduate training, the
curricula in different European countries vary greatly. This vari-
ability limits comparability between countries and international
exchange while carrying consequences in the breadth and quality
of education that trainees receive. Literature and curricula mainly
published in USA as well as a recently published curriculum and
learning catalogue in Germany ffer useful tools for the devel-
opment of a curriculum at a European level.
Conclusions There is clearly a need for standardization of
psychopharmacology-pharmacopsychiatry teaching at the Euro-
pean level. This can be achieved by the introduction of a curriculum
and learning catalogue developed by European experts and based
on tools already available.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Reference
[1] Laux G. Proposal for a model psychopharmacology curriculum
for psychiatric residents in Germany. Psychopharmakotherapie
2014;21:64–8.
W19
Proposal for a model
psychopharmacology curriculum for
psychiatric residents in Germany
G. Laux
Institute of Evidence-based Medicine in Psychopharmacotherapy,
Institute of Psychological Medicine, Haag , Germany
All German societies of medicine have been ordered by the Fed-
eral Association of Physicians (Bundesärztekammer) to propose
new revised regulations for the education of residents. The Ger-
manAssociation for Psychiatry, Psychotherapy and Psychosomatics
(DGPPN) is offering a broad extension of education in psychother-
apy while education in pharmacotherapy is still rather small and
limited. The working group Biological Psychiatry of the German
Association of Psychiatric Hospitals (Bundesdirektorenkonferenz,
BDK) suggests a detailed proposal of a psychopharmacology cur-
riculum based on a Delphi method consent of medical directors
involved in the education of the majority of German psychiatric
residents. Issues include general pharmacology, neurobiological
principles, clinical pharmacology of different classes of psychotrop-
ics (antidepressants, antipsychotics, mood stabilizers, anxiolytics,
hypnotics, stimulants etc.), special aspects (e.g. pregnancy, geri-
atric patients) as well as ethical, legal and economic aspects. About
160 hours of theoretical education are proposed, clinical teach-
ing should be interactive, with vignettes and supervision covering
about 300 hours.
Disclosure of interest The author has not supplied his declaration
of competing interest.
W20
Psychopharmacology during
residents’ training: The role of
scientific societies
P.M. Llorca
Hôpital Gabriel Montpied, Psychiatry department, Clermont-Ferrand,
France
In France, psychopharmacology is supposed to be one of the bases
of the training during the first year of residency. But there is no
standardization in the content of the psychopharmacology courses
for residents from one region to another. There is also a debate
around the way psychopharmacology has to be learned by young
professionals, with the development a narrative approach that
seems to have a pedagogic relevance, opposed to a more aca-
demic approach. In this context, the French Society for Biological
Psychiatry and neuropsychopharmacology developed a program
of specific psychopharmacology workshops for residents. These
workshops combine a fundamental pharmacologic approach, with
a more clinical evidence-based one, trying to take into account the
discrepancy that residents may experienced between knowledge
and every day practice, around specific topics (e.g. polypharma-
cotherapy). This program highlights different issues in the domain
of the psychopharmacology courses for residents around the for-
mat (e.g. on-line courses versus face-to-face courses), the topics
and the content of the courses (e.g. categorical approach of pre-
scription versus dimensional approach). It underlines the need
for a clear definition of what has to be known by residents in
this field but also how this initiative can be implemented for a
large number of residents using numeric tools and what is the
role of scientific societies and their interactions with academic
teaching. The funding of such programs has also to be defined and
clarified.
Disclosure of interest The author has not supplied his declaration
of competing interest.
W21
The new neuroscience based
nomenclature of neuropsychotropic
drugs: A chance for a better
understanding and teaching of
clinical psychopharmacology
H.J. Möller
Psychiatric University Hospital Munich, Munich, Germany
Traditional psychopharmacological terminology is based on his-
torical grounds and under different aspects not systematic and
rational. It even tends to confuse patients by prescribing a
drug that does not reflect their identified diagnosis, prescribing
“antipsychotics” to depression. Four major colleges of neuropsy-
chopharmacology (ECNP, ACNP, Asian CNP, an CINP) proposed
a new multi-axial pharmacologically-driven nomenclature. The
template has five axes: 1- class (primary pharmacological tar-
get and relevant mechanism); 2- family (reflecting the relevant
neurotransmitter and mechanism); 3- neurobiological activities;
4- efficacy and major side effects; and 5- approved indications.
The results of the surveys suggest that the clinicians found the
available indication-based nomenclature system dissatisfactory,
non-intuitive, confusing, and doubt-inducing for them and the
patients. The proposed five-axis template seeks to upend current
usage bay placing pharmacology rather than indication as the pri-
mary axes. With the proposed nomenclature relating primarily to
Axis 1 – the class, and usage of the other axes would largely depend
the extent to which the clinician seeks to deepen the scientific and
clinical base of his involvement.